HOME >> MEDICINE >> NEWS
The long research road to a new vaccine

The Food and Drug Administration (FDA) today announced the licensing of a new vaccine against a disease responsible for tens of thousands of hospitalizations in the United States and hundreds of thousands of deaths around the world each year. The vaccine, developed by Merck & Co., Inc., will be sold as ROTATEQ and will protect infants against rotavirus infection. Rotavirus is a highly contagious virus that is the most common cause of severe dehydrating diarrhea in infants and young children.

The early research that underpins the new vaccine was conducted by three scientists at The Wistar Institute and The Children's Hospital of Philadelphia (CHOP) between 1980 and 1991, at which time Merck took on the task of developing the vaccine for the clinic. The scientists are H. Fred Clark, D.V.M., Ph.D., Paul A. Offit, M.D., and Stanley A. Plotkin, M.D. Clark and Offit are currently on faculty at CHOP, where Clark is a research professor of pediatrics and Offit is chief of infectious diseases and the Maurice R. Hilleman Endowed Chair in Vaccinology; both are adjunct professors at Wistar. Plotkin, an emeritus professor at Wistar, was the developer of a number of vaccines, including the rubella vaccine responsible for eradicating that disease in the United States, according to the Centers for Disease Control.

"This new vaccine against an important disease of childhood is the result of two leading academic research institutions and a major pharmaceutical company working together toward a common goal for roughly 25 years," says Russel E. Kaufman, M.D., president and CEO of The Wistar Institute. "It has been a long road, and we are very proud of the role our scientists played in the success of this important medical advance."

Plotkin and Clark began work on rotavirus in 1980. In 1981, Clark, a veterinarian, isolated from a calf the strain of rotavirus dubbed the Wistar Calf-3, or WC3, strain that would provide the foundation for the new vaccine. That sam
'"/>

Contact: Franklin Hoke
hoke@wistar.org
215-898-3716
The Wistar Institute
3-Feb-2006


Page: 1 2 3

Related medicine news :

1. 1 of 2 pediatric kidney disease research centers in world established
2. Stanford researchers find culprit in aging muscles that heal poorly
3. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
4. Indiana University Imaging Center receives $6M grant for kidney research
5. Penn researchers discover novel pathway for increasing good cholesterol
6. New research discovers independent brain networks control human walking
7. Theory of facial aging gets a facelift from UT Southwestern researchers
8. Sports concussion research using fMRI provides insight for safe return-to-play decisions
9. UIC researchers to develop new drugs to fight bioterrorism
10. New research finds high prevalence of smoking among physicians in China
11. Fat is the new normal, FSU researcher says

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The long research road new vaccine

(Date:5/25/2013)... (PRWEB) May 25, 2013 Today, Zane ... insurance marketplaces . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... the October 1, 2013 open enrollment of the Health ... of the Marketplaces is "Choice, Competition and Clout for ...
(Date:5/25/2013)... Imagine running the air conditioner with the windows open all ... energy! If the home has a folding pull-down attic stair, ... may be just what is occurring in the home every ... in the form of higher energy bills. Drafts are the ... , Drafts occur through the small cracks around doors, windows, ...
(Date:5/25/2013)... NYC,NY (PRWEB) May 25, 2013 Dr. ... only non-invasive procedure FDA-approved to lift skin on the neck, ... available at her practice, Medical Aesthetics. , Ultherapy is a ... body’s own natural healing process to lift the skin over ... the first time, to see and then treat the deepest ...
(Date:5/25/2013)... Communities of Distinction TV announces May ... largest media market in the United States with almost three ... in Texas and a major convention city. Ft. Worth is ... it is home to many major museums. Both cities offer ... the arts. Residents and locals will be able to watch ...
(Date:5/25/2013)... 25 (HealthDay News) -- Many viruses and parasites that ... leptospirosis -- a bacteria-borne illness than can result in ... dog parks, according to a veterinarian. These ... even the air, said Dr. Susan Nelson, a clinical ... "Many of these serious diseases can be fatal, even ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 2Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Hidden Dangers Dog Dog Parks 2
(Date:5/24/2013)... , May 24, 2013 In accordance with ... and Rule 14e-1 of the United States Exchange Act, Echo ... original offer for Elan Corporation (NYSE: ELN). Background ... ("Royalty Pharma") made an offer for the entire of the ... plc ("Elan") (the "Original Offer").  On 20 ...
(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...
(Date:5/23/2013)... SHENYANG, CHINA , May 24, 2013 /PRNewswire/ ... ("3SBio" or the "Company"), a leading ... developing, manufacturing and marketing biopharmaceutical products, announced today ... (the "EGM"), the Company,s shareholders voted in favor ... previously announced agreement and plan of merger dated ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
Cached News: